The WACC of EuBiologics Co Ltd (206650.KQ) is 7.4%.
Range | Selected | |
Cost of equity | 6.60% - 8.40% | 7.50% |
Tax rate | 2.90% - 3.80% | 3.35% |
Cost of debt | 4.00% - 4.50% | 4.25% |
WACC | 6.6% - 8.3% | 7.4% |
Category | Low | High |
Long-term bond rate | 3.1% | 3.6% |
Equity market risk premium | 5.8% | 6.8% |
Adjusted beta | 0.61 | 0.63 |
Additional risk adjustments | 0.0% | 0.5% |
Cost of equity | 6.60% | 8.40% |
Tax rate | 2.90% | 3.80% |
Debt/Equity ratio | 0.03 | 0.03 |
Cost of debt | 4.00% | 4.50% |
After-tax WACC | 6.6% | 8.3% |
Selected WACC | 7.4% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for 206650.KQ:
cost_of_equity (7.50%) = risk_free_rate (3.35%) + equity_risk_premium (6.30%) * adjusted_beta (0.61) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.